Sign In
Buy ANVS
$1.75
-0.0200 (-1.13%)
At Close: Jul 31, 2026
Annovis Bio 2020 Annual Meeting of Stockholders to Be Held on June 3, 2020
10:45am, Monday, 01'st Jun 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, will hold its 202
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
10:00am, Friday, 01'st May 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today an intervi
Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients
10:45am, Thursday, 30'th Apr 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today
How Much Are Annovis Bio, Inc. (NYSEMKT:ANVS) Insiders Spending On Buying Shares?
10:09am, Wednesday, 29'th Apr 2020
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
11:00am, Thursday, 23'rd Apr 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, published data from its two
Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14
09:30pm, Monday, 13'th Apr 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, announced today its CEO Ma
Annovis Bio to Present at the Online Spring Investor Summit on March 25
01:00pm, Thursday, 19'th Mar 2020
NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases, is
Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies
11:45am, Thursday, 27'th Feb 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s (AD) , Parkinson’s (PD) and other neurodegenerative diseases, was awarded a $1.7 million grant
The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace
11:38pm, Sunday, 23'rd Feb 2020
Biotech stocks turned in a lackadaisical performance last week amid earnings releases by smid-cap stocks, a few clinical readouts and data presentations at conferences and a handful of FDA verdicts. M
Stocks To Watch: JPMorgan, Virgin Galactic, Peloton Put To The Test
01:26pm, Saturday, 22'nd Feb 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases
12:00pm, Thursday, 20'th Feb 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, was issued a patent (US 10,383,851) in Augu
Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease
04:40pm, Thursday, 13'th Feb 2020
Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced today that the Data Safety Monito
Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
04:46pm, Friday, 31'st Jan 2020
Annovis Bio, Inc. (NYSE American: ANVS), a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases, today announced the closing of its initial pu
Mid-Day Market Update: Dow Falls 150 Points; Inovio Pharmaceuticals Shares Spike Higher
05:55pm, Thursday, 30'th Jan 2020
Midway through trading Thursday, the Dow traded down 0.52% to 28584 while the NASDAQ fell 0.65% to 9214.83. The S&P also fell, dropping 0.62% to 3253.02.
Leading and Lagging...
